Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
about
Chronic hyperbaric exposure activates proinflammatory mediators in humans.Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunityTrappin-2/elafin modulate innate immune responses of human endometrial epithelial cells to PolyI:CSecretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cellsRegulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafinThe inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps.Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidantsDecreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.Innate host defense functions of secretory leucoprotease inhibitor.Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers.WAP domain proteins as modulators of mucosal immunity.Regulatory mechanisms of injury and repair after hepatic ischemia/reperfusionThe Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity.Anti-tumor effect of SLPI on mammary but not colon tumor growth.Antiproteases as therapeutics to target inflammation in cystic fibrosis.Differential effects of periopathogens on host protease inhibitors SLPI, elafin, SCCA1, and SCCA2.Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema.Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects.Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.Anti-Inflammatory Effect of Pre-Elafin in Lipopolysaccharide-Induced Acute Lung Inflammation
P2860
Q33425268-6F4EED22-3414-4D84-88CE-69D999AF9088Q33780434-0162B768-BC52-4B4C-988D-977520F7A244Q34251265-B8B388E4-AFE8-4378-A538-C1AEF45CEADEQ35022070-53FC7D92-C274-4AE8-8B15-F3364401C48CQ35106451-6E660BCD-688B-4DC2-980D-BAABBE9FF91DQ35741744-3D274C21-FDB8-462E-B05E-6C900EE2A5FBQ36104532-31F2A6F3-4A59-4337-8CF2-FD8B3116D7CFQ36114167-D834B4FE-2CC4-446E-98B6-BE37BF8FFBA2Q37030651-FEAA0E4D-52E5-4514-BED7-BCD618D952F3Q37576058-58777FBB-15D6-4DA9-ACF2-8F6B61AE9823Q37936531-660D1961-8E28-4B85-9539-860F7BE26F78Q38166369-D267CD56-A8D8-4C97-97CB-05126A2DEF3CQ38845999-7A7B638B-0437-4F55-9C7A-AC2B0C047FF1Q39318982-E8BD962A-731E-4828-B39D-57D15BAF19A5Q40363808-5036F8A8-F94B-447E-B2D7-82B78510A4E2Q42723859-45BA5FBE-DE8E-4F7B-AC81-E461C7F5F276Q43075860-D5D57F2D-6950-4480-A252-09CC4795237EQ43705722-4B6D62BB-23C5-4506-B73B-A51C1D5D28D1Q44041891-98E46686-DBC9-45DD-998B-CE600F0B9AA6Q58376952-7EFB0908-3854-4E34-99C9-5D51D68EB081
P2860
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@ast
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@en
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@nl
type
label
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@ast
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@en
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@nl
prefLabel
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@ast
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@en
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@nl
P2093
P2860
P1476
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor
@en
P2093
A B Lentsch
C D Wright
M Huber-Lang
M S Mulligan
P2860
P304
P356
10.1016/S0002-9440(10)64971-1
P407
P577
2000-03-01T00:00:00Z